Clinical Trial Update: Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating Angiomax (bivalirudin) versus unfractionated heparin in patients undergoing percutaneous coronary intervention has been terminated. Spo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Angiomax (bivalirudin)
• Unfractionated Heparin (unfractionated heparin)

Snippet

Sponsor: Stony Brook University | Conditions: Coronary Artery Disease | Phase 4 | Status: TERMINATED